Argentina and Brazil join forces to produce AIDS drugs

NewsGuard 100/100 Score

Argentina's Health Ministry has announced that in partnership with the Brazilian government they plan to produce their own anti-AIDS drugs in an effort to lower the cost of treatment.

The construction of a $10 million jointly owned plant, possibly to be located in Argentina, will begin within a few months.

The announcement was made following a meeting in Brasilia between Health Minister Gines Gonzales and his Brazilian counterpart, Jose Saraiva Felipe.

Both countries already provide free medication and treatment to all HIV-positive patients.

Gonzalez says they aim to produce the most expensive treatment items in order to be able to provide the best for those who need it.

In recent years, by threatening to break patents and locally produce copycat versions, the Brazilian government has successfully forced foreign-owned drug companies to lower prices on AIDS medicines on several occasions.

Brazil currently makes some anti-AIDS drugs that are not covered by patents and has agreed with Argentina to conduct joint research to develop drugs.

Health official have long argued that paying for medication is cheaper in the long run than having people in intensive care in public hospitals.

Brazil is justly proud of it's AIDS program which has helped bring about a fall in the spread of the virus.

At present Argentina spends about $60 million a year to treat some 30,000 patients while Brazil provides treatment for 160,000 people.

The joint drug venture will also produce drugs to treat the deadly Chagas disease, transmitted by a blood-sucking parasite, and leishmaniasis, a skin disease also caused by an insect.

According to the United Nations, as many as 1.8 million Latin Americans are infected with the HIV-AIDS virus, with Brazil, Argentina and Colombia the worst affected.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative malaria prodrug targets liver, enhances efficacy while reducing toxicity, preclinical studies show